• Zhengye Biotechnology received a Nasdaq notice for failing the US$ 1 minimum bid-price rule after 30 straight business days below the threshold.
• Nasdaq set a compliance deadline of Nov. 25, 2026; shares must close at or above US$ 1 for 10 consecutive business days.
• Non-compliance could trigger delisting risk; the stock remains listed for now during the cure period.
• Management is weighing steps to regain compliance, including a potential reverse share split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041605PRIMZONEFULLFEED9732008) on June 04, 2026, and is solely responsible for the information contained therein.